REG - Hikma Pharmaceutical - Director/PDMR Shareholding <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

19/03/2015 13:52

RNS Number : 9336H
Hikma Pharmaceuticals Plc
19 March 2015
Hikma Pharmaceuticals PLC - Vesting of 2012 LTIP
LONDON, 19 March 2015: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards on 19 March 2015 under the 2005 Long Term Incentive Plan ("LTIP"). These awards were automatically exercised by operation of the conditional award and vesting process. The exercise price under the LTIP is nil. The persons concerned have retained all the shares exercised.
In accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, Hikma announces that the following transactions took place in London over the Company's Ordinary Shares of 10p each as detailed below.
Bassam Kanaan
Vesting of LTIP 2012
46,300
(0.02% ISC)
19 March 2015
22.26
Nil
500,390
(0.25% ISC)
Michael Raya
Vesting of LTIP 2012
43,800
(0.02% ISC)
19 March 2015
22.26
Nil
119,960
(0.06% ISC)
Riad Mishlawi
Vesting of LTIP 2012
20,700
(0.01% ISC)
19 March 2015
22.26
Nil
100,027
(0.05% ISC)
Khalid Nabilsi
Vesting of LTIP 2012
26,000
(0.01% ISC)
19 March 2015
22.26
Nil
222,858
(0.11% ISC)
"ISC" = Issued Share Capital of Hikma which is 198,879,939 Ordinary Shares following the release of the LTIP 2012
- ENDS -
Enquiries 
Peter Speirs   +44 20 7399 2760
Company Secretary, Hikma Pharmaceuticals PLC
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RDSBXGDXSSBBGUC